108 assets in Prostate Carcinoma

Therapeutic assets addressing Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Prostate Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
T-Cell Receptor-Engineered T-Cells Prostate Carcinoma	Fred Hutchinson Cancer Center	P1	C (39)
Urea Prostate Carcinoma	Ivan de Kouchkovsky, MD	Early P1	C (39)
Vemurafenib Prostate Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Vinorelbine Ditartrate Prostate Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Vudalimab Prostate Carcinoma	Emory University	P1	C (37)
(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine Prostate Carcinoma	Nuvation Bio Inc.	P1/2	C (32)

Showing 101 to 108 of 108 assets

PreviousPage 3 of 3Next